Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

Autor: Li, Grace, Cappuccini, Federica, Marchevsky, Natalie G, Aley, Parvinder K, Aley, Robert, Anslow, Rachel, Bibi, Sagida, Cathie, Katrina, Clutterbuck, Elizabeth, Faust, Saul N, Feng, Shuo, Heath, Paul T, Kerridge, Simon, Lelliott, Alice, Mujadidi, Yama, Ng, Khuen Foong, Rhead, Sarah, Roberts, Hannah, Robinson, Hannah, Roderick, Marion R, Singh, Nisha, Smith, David, Snape, Matthew D, Song, Rinn, Tang, Karly, Yao, Andy, Liu, Xinxue, Lambe, Teresa, Pollard, Andrew J, Aboagye, J, Ambihapathy, W, Baker, JF, Beales, ER, Boon, A, Brampton, R, Branch, NM, Cooper, R, Cornish, EL, Cuevas-Asturias, S, Danos, Z, Davies, S, de Luna George, L, Drury, R, Flaxman, A, Fowler, J, Galiza, E, Godfrey, L, Haskell, L, Hillson, K, Hultin, CL, Koleva, S, Lees, E, Mabbett, R, Muller, J, Munro, APS, Oliver, AL, Owens, DR, Pearce, JP, Rajan, M, Ratcliffe, H, Rowbotham, I, Salter, S, Sanders, H, Sapuan, SS, Sharpe, H, Sheehan, E, Sutton, N, Thaygaraja, G, Thomson-Hill, S, Ulaszewska, M, Woods, D, Team, Bristol Clinical Research Nurse

Publikováno v: The Lancet; June 2022, Vol. 399 Issue: 10342 p2212-2225, 14p